The Most Important Advances in Precision Medicine Being Presented at ASCO 2018Video Categories: 2018 ASCO Insights, Biomarkers, and Video Library
Dr David Spigel reviews 3 of the most important, practice-changing topics at ASCO 2018: new therapies targeting RET in a number of tumor types, a prognostic biomarker assay to predict whether patients with breast cancer will need adjuvant hormonal therapy or chemotherapy, and the minimum level of PD-L1 positivity required to predict outcomes with immunotherapy in lung cancer.
Dr. Jorge Cortes ponders the cost of treatment versus the improvement in the standard of care, asking if what we are gaining is really worth the rising cost.
Drs. Goeffrey Oxnard and Lauren Ritterhouse review how the results of PD-L1 testing influence the choices in first- or second-line immunotherapy or combination immunochemotherapy in patients with squamous or non-squamous non-small-cell lung cancer.